Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - nadroparin calcium - solution for injection - 7600iu ant international unit

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - nadroparin calcium - solution for injection - 9500iu ant international unit

India - English - Central Drugs Standard Control Organization

gsk - l m w h - inj - 8600i.u. (nadroparin)

India - English - Central Drugs Standard Control Organization

sanofi aventis - l m w h - inj - 4100 i.u.(nadroparin) - 0.4ml ps

India - English - Central Drugs Standard Control Organization

sanofi aventis - l m w h - inj - 6150 i.u.(nadroparin) - 0.6ml ps

India - English - Central Drugs Standard Control Organization

sanofi aventis - l m w h - inj - 8600i.u. (nadroparin) - 0.8mlps

India - English - Central Drugs Standard Control Organization

sanofi aventis - l m w h - 3075 i.u.(nadroparin) - 0.3ml

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - nadroparin calcium 19000 anti-xa iu/ml - solution for injection - 19000 anti-xa iu/ml - active: nadroparin calcium 19000 anti-xa iu/ml excipient: calcium hydroxide hydrochloric acid water for injection - treatment of deep vein thrombosis

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - nadroparin calcium 3800 iu / 0.4 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during heamodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - nadroparin calcium 2850 iu / 0.3 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during haemodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.